Evidence map›Paper›PMID 19683019›Full record

ReviewPharmacology & therapeutics2009

Anti-relapse medications: preclinical models for drug addiction treatment.

Noushin Yahyavi-Firouz-Abadi, Ronald E See

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Modeling the development of drug addiction in male and female animals.Pharmacology, biochemistry, and behavior · 2018
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. The selective dopamine β-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Article
  17. Development of κ opioid receptor antagonists.Journal of medicinal chemistry · 2013
    Review
  18. Article
  19. Article
  20. Novel cues reinstate cocaine-seeking behavior and induce Fos protein expression as effectively as conditioned cues.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Noushin Yahyavi-Firouz-AbadiDepartment of Neurosciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Ronald E See
Medical University of South Carolina · US

Funding

Selective Restoration of KCNQ Channel Inhibition in the PFC to Inhibit Cue-InducP50DA015369 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ASTON-JONES, GARY S. · 2003 to 2017
$18.6M
Vocational Training for Drug Dependent WomenP50DA016511 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2002 to 2017
$14.5M
Translational Research in Addiction CenterP20DA022658 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KALIVAS, PETER W · 2006 to 2009
$3.0M
Striatal mechanisms of relapse to cocaine seekingR01DA010462 · NIDA · WASHINGTON STATE UNIVERSITY · PI REICHEL, CARMELA M · 1997 to 2012
$2.7M
Interdisciplinary Medication Development for Multiple Risk Factors in RelapseR01DA021690 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SEE, RONALD E · 2007 to 2011
$1.8M
NIDA NIH HHS DA10462NIDA NIH HHS DA15369NIDA NIH HHS DA16511NIDA NIH HHS DA21690NIDA NIH HHS DA22658NIDA NIH HHS P20 DA022658NIDA NIH HHS P50 DA015369NIDA NIH HHS P50 DA016511NIDA NIH HHS R01 DA010462NIDA NIH HHS R01 DA021690
6 · The paper itself

Abstract

Addiction is a chronic relapsing brain disease and treatment of relapse to drug-seeking is considered the most challenging part of treating addictive disorders. Relapse can be modeled in laboratory animals using reinstatement paradigms, whereby behavioral responding for a drug is extinguished and then reinstated by different trigger factors, such as environmental cues or stress. In this review, we first describe currently used animal models of relapse, different relapse triggering factors, and the validity of this model to assess relapse in humans. We further summarize the growing body of pharmacological interventions that have shown some promise in treating relapse to psychostimulant addiction. Moreover, we present an overview on the drugs tested in cocaine or methamphetamine addicts and examine the overlap of existing preclinical and clinical data. Finally, based on recent advances in our understanding of the neurobiology of relapse and published preclinical data, we highlight the most promising areas for future anti-relapse medication development.

Indexed as

Disease Models, AnimalAnimalsBehavior, AddictiveControlled Clinical Trials as TopicDopamine AgentsHumansSecondary PreventionSubstance-Related DisordersDopamine Agents

Identifiers

PMID19683019
PMCPMC2889132
OpenAlexW1974504536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.